Takeda Pharmaceutical Company Limited announced its results for the second quarter of the fiscal year ending March 2027 on 29 October 2026, and said it is filing applications in the US and Europe for the psoriasis treatment zasocitinib. A domestic application for the ADC for third-line treatment of gastric cancer is scheduled for 2027. The latest clinical data were also presented.
Takeda Pharmaceutical Company Limited published its results for the second quarter of the fiscal year ending March 2027 and held a results briefing. Clinical data for the psoriasis treatment zasocitinib (TAK-279) and the anticancer drug ARCOTATUG TAVATECAN (development code TAK-921) were explained.
The company said it is filing applications in the US and Europe for the psoriasis treatment zasocitinib, with the status of applications in the US and European markets emphasised.
It was reported that a domestic application for the ADC for third-line treatment of gastric cancer is expected to be filed in 2027.
The latest clinical data for TAK-921 were presented at the briefing.